← Eichor
Study identifier: NCT05796401 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis

Condition: Psychosis  ·  Sponsor: Centre Hospitalier St Anne

PhasePhase 3
Planned participants500
Who can joinAll sexes, 15 Years to 30 Years
Healthy volunteersNo

About this study

Chronic psychosis, including schizophrenia is now viewed as a progressive disorder where cognitive deficits predate the clinical onset. Early intervention programs improve the general outcome with staged care strategies, supporting the view that the period before and around the first episode of psychosis is a window of opportunity for improving its functional recovery. Pioneering epigenetic analyses indicate that psychosis onset involves oxidative stress and inflammation suggesting that neuroprotective strategies could limit or even prevent the onset of or the transition into a chronic disorder. Several biological factors associated with the emergence of psychosis can all be rectified by using safe and easily accepted supplements including alterations folate deficiency/hyperhomocysteinemia; redox imbalance and deficit in polyunsaturated fatty acids (PUFA). The prevalence of these anomalies (20-30%) justifies a systematic detection and could guide personalised add-on strategy. Cognitive remediation improves quality of life (QoL) and functional outcome in patients with chronic psychosis. It would even be more efficacious in the early phase of psychosis by tackling the negative impact of psychosis on education achievement and employment. However, cognitive dysfunctions are often overlooked in patients at ultra-high risk (UHR) for psychosis and patient with a first episode of psychosis (FEP) and cognitive remediation is not always accessible. New technologies can provide us wit…

This description comes directly from the study's public registry record.

Talk to the study team

Marie-Odile KREBS  ·  +33 1 45 65 74 97  ·  marie-odile.krebs@inserm.fr

Khaoussou SYLLA  ·  +331.45.65.73.35  ·  K.SYLLA@ghu-paris.fr

Always discuss trial participation with your own doctor first.

Locations (13)

CHRU BrestBrest, FranceRecruiting
Centre Esquirol - CHU CAENCaen, FranceRecruiting
CHU Clermont FerrandClermont-Ferrand, FranceRecruiting
Centre Hospitalier La ChartreuseDijon, FranceNot Yet Recruiting
Hôpital FontanLille, FranceRecruiting
Hôpital La Colombière - CHU MontpellierMontpellier, FranceRecruiting
Eldorado - Maison des Adolescents de Meurthe et MoselleNancy, FranceRecruiting
CH OrsayOrsay, FranceRecruiting
GHU Paris Neurosciences PsychiatrieParis, FranceRecruiting
Nineteen GHUParis, FranceNot Yet Recruiting
CHU PoitiersPoitiers, FranceRecruiting
C.H. Guillaume RegnierRennes, FranceRecruiting

+ 1 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05796401